InMed Pharmaceuticals (INM) Cash from Operations (2019 - 2026)

InMed Pharmaceuticals has reported Cash from Operations for 8 years, with the latest figure at -$1.7 million in Q1 2026.

• On a quarterly basis, Cash from Operations fell 2.15% year-over-year to -$1.7 million in Q1 2026; TTM through Mar 2026 was -$7.5 million, a 6.27% decrease from a year earlier, with the FY2025 full-year figure at -$7.8 million, down 11.18% from the prior year.
• Cash from Operations was -$1.7 million for Q1 2026 at InMed Pharmaceuticals, up from -$2.4 million in the prior quarter.
• The five-year high for Cash from Operations was -$657934.0 in Q2 2023, with the low at -$5.3 million in Q1 2022.
• Average Cash from Operations over 5 years is -$2.2 million, with a median of -$1.8 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2023: Cash from Operations plunged 101.75% in 2022, then soared 83.74% in 2023.
• Over 5 years, Cash from Operations stood at -$2.7 million in 2022, then soared by 31.88% to -$1.8 million in 2023, then plunged by 35.39% to -$2.5 million in 2024, then increased by 5.03% to -$2.4 million in 2025, then rose by 28.66% to -$1.7 million in 2026.
• The last three Cash from Operations figures came in at -$1.7 million (Q1 2026), -$2.4 million (Q4 2025), and -$1.6 million (Q3 2025), per Business Quant data.